A.RBC4.0×1012/L,Hb75g/L,MCV63fl,MCH22pg,MCHC0.25,網(wǎng)織紅細(xì)胞0.010
B.RBC2.3×1012/L,Hb85g/L,MCV94fl,MCH35pg,MCHC0.35,網(wǎng)織紅細(xì)胞0.015
C.RBC2.0×1012/L,Hb60g/L,MCV84fl,MCH30pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.003
D.RBC4.5×1012/L,Hb115g/L,MCV83fl,MCH31pg,MCHC0.34,網(wǎng)織紅細(xì)胞0.015
E.RBC2.2×1012/L,Hb63g/L,MCV81fl,MCH32pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.09
您可能感興趣的試卷
你可能感興趣的試題
A.RBC4.0×1012/L,Hb75g/L,MCV63fl,MCH22pg,MCHC0.25,網(wǎng)織紅細(xì)胞0.010
B.RBC2.3×1012/L,Hb85g/L,MCV94fl,MCH35pg,MCHC0.35,網(wǎng)織紅細(xì)胞0.015
C.RBC2.0×1012/L,Hb60g/L,MCV84fl,MCH30pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.003
D.RBC4.5×1012/L,Hb115g/L,MCV83fl,MCH31pg,MCHC0.34,網(wǎng)織紅細(xì)胞0.015
E.RBC2.2×1012/L,Hb63g/L,MCV81fl,MCH32pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.09
A.RBC4.0×1012/L,Hb75g/L,MCV63fl,MCH22pg,MCHC0.25,網(wǎng)織紅細(xì)胞0.010
B.RBC2.3×1012/L,Hb85g/L,MCV94fl,MCH35pg,MCHC0.35,網(wǎng)織紅細(xì)胞0.015
C.RBC2.0×1012/L,Hb60g/L,MCV84fl,MCH30pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.003
D.RBC4.5×1012/L,Hb115g/L,MCV83fl,MCH31pg,MCHC0.34,網(wǎng)織紅細(xì)胞0.015
E.RBC2.2×1012/L,Hb63g/L,MCV81fl,MCH32pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.09
A.RBC4.0×1012/L,Hb75g/L,MCV63fl,MCH22pg,MCHC0.25,網(wǎng)織紅細(xì)胞0.010
B.RBC2.3×1012/L,Hb85g/L,MCV94fl,MCH35pg,MCHC0.35,網(wǎng)織紅細(xì)胞0.015
C.RBC2.0×1012/L,Hb60g/L,MCV84fl,MCH30pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.003
D.RBC4.5×1012/L,Hb115g/L,MCV83fl,MCH31pg,MCHC0.34,網(wǎng)織紅細(xì)胞0.015
E.RBC2.2×1012/L,Hb63g/L,MCV81fl,MCH32pg,MCHC0.33,網(wǎng)織紅細(xì)胞0.09
A.血紅蛋白測(cè)定
B.血清鐵蛋白測(cè)定
C.紅細(xì)胞游離原卟啉測(cè)定
D.血清鐵測(cè)定
E.血清總鐵結(jié)合力
A.血紅蛋白測(cè)定
B.血清鐵蛋白測(cè)定
C.紅細(xì)胞游離原卟啉測(cè)定
D.血清鐵測(cè)定
E.血清總鐵結(jié)合力
最新試題
下面哪一項(xiàng)符合急性ITP的檢查結(jié)果()
蠶豆病的發(fā)生常常于進(jìn)食蠶豆后哪一時(shí)間段發(fā)?。ǎ?/p>
機(jī)體在缺鐵性貧血階段,其相關(guān)檢測(cè)結(jié)果中下列哪項(xiàng)是正確的()
下列哪一項(xiàng)有關(guān)營(yíng)養(yǎng)性巨幼細(xì)胞貧血的治療是正確的()
小兒惡性淋巴瘤骨髓受累,伴淋巴結(jié)腫大屬于哪一臨床分期()
ITP的主要臨床特點(diǎn)是()
口服鐵劑治療時(shí)采取下列哪一項(xiàng)措施能夠促進(jìn)鐵的吸收()
目前非霍奇金淋巴瘤的治療主要是()
關(guān)于家族性噬血細(xì)胞綜合征的預(yù)后正確的是()
大劑量甲氨蝶呤應(yīng)用于兒童急性淋巴細(xì)胞白血病的主要目的是()